HB Wealth Management LLC Purchases 5,516 Shares of Gilead Sciences, Inc. $GILD

HB Wealth Management LLC lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.7% in the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 56,970 shares of the biopharmaceutical company’s stock after acquiring an additional 5,516 shares during the period. HB Wealth Management LLC’s holdings in Gilead Sciences were worth $7,940,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences in the fourth quarter worth $25,000. Vermillion & White Wealth Management Group LLC boosted its holdings in shares of Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 85 shares in the last quarter. Quattro Advisors LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter worth about $26,000. Wealth Preservation Advisors LLC grew its position in shares of Gilead Sciences by 60.0% in the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 81 shares during the period. Finally, Ares Financial Consulting LLC bought a new position in shares of Gilead Sciences in the 4th quarter worth about $28,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the completion of the sale, the chief executive officer owned 617,567 shares in the company, valued at approximately $81,185,357.82. This represents a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the transaction, the chief financial officer directly owned 171,646 shares in the company, valued at approximately $21,524,408.40. This represents a 1.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 83,000 shares of company stock valued at $10,824,500 in the last ninety days. 0.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of recent research reports. Citigroup lifted their price target on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research note on Wednesday, May 20th. Leerink Partners lowered their target price on shares of Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Royal Bank Of Canada reissued a “sector perform” rating on shares of Gilead Sciences in a research report on Monday, June 8th. Finally, Rothschild & Co Redburn cut their price target on Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Twenty-five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $158.41.

Gilead Sciences Price Performance

GILD opened at $131.27 on Friday. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The firm has a 50 day moving average price of $129.44 and a 200-day moving average price of $134.53. Gilead Sciences, Inc. has a twelve month low of $107.75 and a twelve month high of $157.29. The stock has a market capitalization of $162.98 billion, a price-to-earnings ratio of 17.88 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter in the prior year, the firm earned $1.81 earnings per share. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post -0.8 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend was Monday, June 15th. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.